WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.
Post approval under the PLI scheme, Aurobindo will become a very large player in anti-biotic space.
Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar.
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business
The phase 3 clinical trial of Sputnik V will be conducted on 1,500 subjects as part of the randomized, double blind, parallel group placebo controlled study in India.
Novasep's viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally," said Michel Lagarde, executive vice president, Thermo Fisher.
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
In FY 2020-2021 (upto 12th January 2021) Jan Aushadhi Kendras have completed sales of Rs. 484 crores at 7,064 Pradhan Mantri Bhartiya Jan Aushadhi Kendras
Subscribe To Our Newsletter & Stay Updated
